KRAS and non-small cell lung carcinoma: The study included more than 500 patients previously treated, and the association of MEK inhibition and chemotherapy did not improve PFS compared with docetaxel alone in KRAS-mutated NSCLC (3.9 vs. 2.8 months; HR 0.93, p = 0.44); the median OS was 8.7 months with selumetinib + docetaxel and 7.9 months with placebo + docetaxel (HR, 1.05; p = 0.64) [36].